Objectives The patients with hematological malignancies are a vulnerable group to COVID-
19, due to the immunodeficiency resulting from the underlying disease and oncological …

Background. The lack of effective etiotropic therapy for COVID-19 has prompted researchers
around the globe to seekr various methods of SARS-CoV-2 elimination, including the use of …

The recent coronavirus disease 2019 (COVID-19) epidemic is spreading all over the world.
By March 23, over 300,000 patients had been confirmed and almost 15,000 died because of …

Convalescent plasma (CP) transfusion has been indicated as a promising therapy in the
treatment for other emerging viral infections. However, the quality control of CP and …

Abstract Introduction South America is one of the regions most affected by the COVID‐19
pandemic. Specific and affordable treatments are needed to treat SARS‐CoV‐2 infection …

Abstract Objectives General: To assess the safety, efficacy and dose response of
convalescent plasma (CP) transfusion in severe COVID-19 patients Specific: a. To identify …

Background Convalescent plasma has been used for a long time for the treatment of various
infectious diseases. The principle is to collect antibody-containing plasma from recovered …

In these times of COVID-19 pandemic, concern has been raised about the potential effects of
SARS-CoV-2 infection on immunocompromised patients, particularly on those receiving B …

Currently, there are no approved specific antiviral agents for novel coronavirus disease
2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test …

Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life
of several hundred thousand worldwide. However, so far no approved vaccine or drug …